The amount of clinical data relating to medical cannabis research is growing at an unprecedented rate, fueling demand for systems that can disseminate critical information to stakeholders.
These are exciting times for the medical cannabis industry. After decades of research being held back by legal restrictions, the barriers are finally coming down. While THC-rich cannabis still retains Schedule 1 status in the United States, numerous states have legitimized medical and recreational cannabis markets, and dozens of other countries around the world have legitimized cannabis consumption. With each jurisdiction that opens up to the medical cannabis market, opportunities arise for medical cannabis research to take place.
For decades now, Israel has been a haven for medical cannabis research, and, in recent years, Canada has also become a hotbed for cannabis-related studies. Our base of knowledge of the therapeutic potential of medical cannabis is growing more quickly than ever before. For medical cannabis stakeholders, it can be difficult to keep up.
Researchers, physicians and other stakeholders require up to date and verifiable cannabis data to make critical medical decisions. To meet this need, the cannabis industry is teaming up with data technology companies to build cannabis-focused data systems meant to help medical professionals, researchers and others stay informed on the rapidly evolving world of medical cannabis.
Clinical data enabling medical cannabis
While hesitation around medical cannabis still exists in the medical community, cannabis is taking on a greater role in mainstream medicine. The ongoing opioid crisis has highlighted a desperate need for non-opioid pain treatments, which has fueled renewed interest in cannabis as a potential treatment method. Several medical cannabis states, including New York, New Jersey and Pennsylvania, have issued guidelines urging physicians to consider cannabis pain treatments as an alternative to opioids. Beginning in 2011, the emergence of CBD as a life-changing treatment for children suffering from severe epileptic disorders has received widespread public attention. Medical organizations like the Canadian Pharmacists Association are now seriously examining clinical data to determine the efficacy of cannabis treatments for a wide range of conditions in order to provide guidance to their members.
The buzz around medical cannabis is driving increased interest from patients and this demand is leading to rapid growth in the space. The global medical cannabis industry is projected to be worth more than US$37 billion by 2023, up from more than US$11 billion in 2017, for a compound annual growth rate of 22 percent, according to data by Research and Markets. In a December 2018 document on medical cannabis, the Mayo Clinic acknowledges that “clinicians are increasingly being asked by patients to share information about or certify them for medical cannabis,” and that clinicians need to be able to provide accurate knowledge about medical cannabis risks and benefits in their conversations with patients.
Clinical data closing the knowledge gap
Researchers are making significant progress in closing the gap in medical cannabis knowledge that has come from decades of excessively strict cannabis prohibition. We now know far more about how cannabis reacts with the human endocannabinoid system and how that process relates to the brain’s reaction to pain and other stimuli. The sheer volume of data being generated on the subject of medical cannabis today is unprecedented, which has led to a new problem. Because so much of our knowledge on the subject is relatively new, access to the information is not always available. As cannabis research continues to progress, medical professionals must be provided greater access to the information they need to make informed medical decisions.
In its 2018 “Real-World Evidence Benchmark Survey,” Deloitte Insights notes that 65 percent of biopharma industry leaders feel that they lack access to adequate external data, and the medical cannabis industry is no exception. The introduction of cannabis data systems that link industries to the latest research from the medical community could provide product builders with an invaluable asset to develop innovative, evidence-based solutions to pressing public health concerns. The need for data-driven insights in medical cannabis presents an opportunity to data technology companies that can bridge the gap between patients, physicians and cannabis product developers.
Nearly every sector of the medical cannabis space could benefit from greater access to data. Even in the most established legal cannabis jurisdictions, the regulatory schemes are still developing as more information pertinent to regulatory standards becomes available. The same comprehensive data systems that help the cannabis industry, medical professionals and patients make informed decisions could also be useful for regulatory agencies and government bodies as they draft evidence-based policy to govern the industry. As more jurisdictions open to legal cannabis, the availability of improved research data could help government policymakers avoid the pitfalls faced by their predecessors in early cannabis markets.
Data solutions supporting medical cannabis
The opportunity presented by the need for clinical data in the cannabis industry is not lost on data tech companies. CB2 Insights (CSE:CBII) currently operates 28 medical cannabis evaluation and education clinics in nine US states plus the District of Columbia. The next step for CB2 is to develop a data platform based on information generated by its partnering clinics. The company’s mission is to help bring cannabis into mainstream healthcare by providing a source for real-world evidence for stakeholders to work with.
Data technology company Cannvas MedTech (CSE:MTEC) is also developing its own crowdsourced cannabis data system. The company’s platform Cannvas Data generates insights from Cannvas’ own Cannvas.me educational program on consumer tastes, needs and habits. Through this approach, Cannvas hopes to produce the “census data of the cannabis industry.”
Knowledge and understanding of cannabis is key to its legitimacy as a mainstream form of medicine. As cannabis establishes itself as a major industry, the need for reliable and comprehensive sources of information has become all the more important. For companies capable of providing this data, the lack of cannabis-related research remains a significant opportunity. Cannabis data systems could play a key role in the future of medical cannabis.
This article was originally published by the Investing News Network in June 2019.
INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.
The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company.
In the evolving rush of mergers and acquisitions (M&A) in the Canadian cannabis market, Canopy Growth (NASDAQ:CGC,TSX:WEED) announced it will acquire The Supreme Cannabis Company (TSX:FIRE,OTCQX:SPRWF) in a deal worth approximately C$435 million.
Meanwhile, a cannabis operator in the US confirmed this week that it will receive a financial boost from a partner to solidify its position in the burgeoning Pennsylvania state market.
The Board of Directors of Aphria Unanimously Recommends Shareholders Vote “For” the Arrangement
Aphria to Host Special Meeting of Shareholders on Wednesday, April 14, 2021 to Approve Proposed Aphria-Tilray Business Combination
Love Hemp Group PLC (AQSE: LIFE) (OTCQB: WRHLF), one of the UK’s leading CBD and Hemp product suppliers, announces that as part of the equity fundraise announced yesterday, Antony Calamita and Andrew Male, Directors of the Company, subscribed for 285,714 Ordinary Shares and 1,428,571 Ordinary Shares respectively. The subscriptions are at a price of 3.5 pence per ordinary share for a total of £60,000. Following these subscriptions, Antony Calamita is now interested in 54,385,714 Ordinary Shares, representing 8.61% of the Company’s share capital as increased by the fundraising, and Andrew Male is now interested in 6,138,196 Ordinary Shares, representing 0.97% of the Company’s issued share capital as increased by the fundraising
Further, the timetable for receipt of applications under the Broker Option, which was also announced yesterday, has been extended until 5:00 pm 9 April 2021 to capture additional interest which was unable to be completed yesterday.
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, would like to provide the following dial-in information for the Company’s upcoming Annual and Special Meeting (the “Meeting”) scheduled to be held at 11:00 a.m. Eastern Daylight Time on April 12, 2021. Shareholders and proxyholders may access the Meeting via teleconference by dialing 647-723-3984 or 1-866-365-4406 from Canada or the United States, then entering participation code “8487744” followed by the pound (“#”) sign.
In consideration of the COVID-19 pandemic and the recent restrictions imposed by the Ontario Provincial Government, shareholders and proxyholders will only be able to attend the Meeting via teleconference and will not be permitted to attend the Meeting in person at the address provided on the Notice of Annual and Special Meeting of Shareholders.
Gage Cannabis Announces Exclusive Partnership With Blue River to Bring Award-Winning Cannabis Extracts to Michigan
Gage Growth Corp. (“Gage” or the “Company”) (CSE:GAGE), a leading high-quality craft cannabis brand and operator in Michigan, announced today that it has signed an agreement with Blue River™ Extracts & Terpenes (“Blue River™”) to bring the brand’s award-winning solventless technology and other trademark branded products to the state’s medical patients and cannabis consumers. The Company will have exclusive rights to Blue River™’s premium product offerings in Michigan.